Genetics

A Myriad of Problems for Myriad: No Patents for Genes, Major Insurer Cuts Back on Genetic Testing

A Myriad of Problems for Myriad: No Patents for Genes, Major Insurer Cuts Back on Genetic Testing
Share

By Layne Feldman Over the past year, two developments—one legal, and one economic—have hit Myriad Genetics, Inc. hard. These developments could have significant ramifications on the detection and treatment of cancer. First, last summer, the Supreme Court ruled that Myriad could not patent the isolated BRCA 1 and BRCA 2 genes that the company used […]

Share

Continue Reading »

Direct to Consumer Genetic Testing and the Over-Production of Genetic Information

Direct to Consumer Genetic Testing and the Over-Production of Genetic Information
Share

Cross Posted at HealthLawProf Blog 23andMe, the Internet genetic testing company, which offered genetic testing for health conditions and ancestry, has received extensive publicity in recent months. In November 2013, the FDA ordered 23andMe to stop marketing its health-related genetic test results to customers because their product is a “device”, which requires FDA approval. In […]

Share

Continue Reading »

Direct to Consumer Genetic Testing — The Need for Early Filtering of Genetic Information

Direct to Consumer Genetic Testing — The Need for Early Filtering of Genetic Information
Share

[Ed. Note: We are pleased to welcome Professor Gaia Bernstein to Health Reform Watch. Articles about her recent scholarship, “Over-parenting,” may be found at the ABA Journal and The New York Times Magazine.] Genetic testing for adult onset diseases used to be mainly a medical service. In most cases a person who had a certain genetic disease […]

Share

Continue Reading »